T-cell/histiocyte rich large B cell lymphoma

disease

On this page

Also known as T-cell rich/histiocyte-rich large B-cell lymphomaT-cell/histiocyte rich lymphomaT-cell/histiocyte-rich large B-cell lymphomaTHRLBCL

Summary

T-cell/histiocyte rich large B cell lymphoma (MONDO:0017597) is a cancer and 15 clinical trials. Top therapeutic interventions include cyclophosphamide anhydrous, acalabrutinib, and azacitidine. A subtype of diffuse large B-cell lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Classification: Cancer
Prevalence: <1 / 1 000 000 (United States) [Orphanet-validated]
Clinical trials: 15

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000	0.023	United States	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	T-cell/histiocyte rich large B cell lymphoma
Mondo ID	MONDO:0017597
Orphanet	300857
ICD-11	257833622
NCIT	C9496
UMLS	C1321547
MedGen	232943
GARD	0012257
Is cancer (heuristic)	yes

Also known as: T-cell rich/histiocyte-rich large B-cell lymphoma · T-cell/histiocyte rich lymphoma · T-cell/histiocyte-rich large B-cell lymphoma · THRLBCL

Disease family

This is a subtype of diffuse large B-cell lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › neoplasm of mature B-cells › diffuse large B-cell lymphoma › T-cell/histiocyte rich large B cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	9
PHASE1	4
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04799275	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
NCT03038672	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT05202782	PHASE2	ACTIVE_NOT_RECRUITING	Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin’s Lymphoma or Transformed Indolent B-cell Lymphoma
NCT05507541	PHASE2	ACTIVE_NOT_RECRUITING	TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT05583149	PHASE2	ACTIVE_NOT_RECRUITING	Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
NCT05821088	PHASE2	RECRUITING	Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
NCT05934448	PHASE2	RECRUITING	Pembro Plus CAR T-cell Therapy in R/R in PMBCL
NCT06649812	PHASE2	RECRUITING	Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
NCT06834373	PHASE2	RECRUITING	Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
NCT07097363	PHASE2	RECRUITING	Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
NCT03704714	PHASE1/PHASE2	SUSPENDED	Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
NCT04231877	PHASE1	RECRUITING	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
NCT05544019	PHASE1	RECRUITING	Study of SGR-1505 in Mature B-Cell Neoplasms
NCT06544265	PHASE1	RECRUITING	SynKIR-310 for Relapsed/Refractory B-NHL
NCT03742258	PHASE1	COMPLETED	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	5
ACALABRUTINIB	4	1
AZACITIDINE	4	1
EPCORITAMAB	4	1
GLOFITAMAB	4	1
POLATUZUMAB VEDOTIN	4	1
TAFASITAMAB	4	1
ZANUBRUTINIB	4	1
GOLCADOMIDE	3	1
LISOCABTAGENE MARALEUCEL	3	1
MAPLIRPACEPT	2	1
ONTORPACEPT	2	1
VARLILUMAB	2	1
SGR-1505	1	1
CHEMBL5193128	0	1
CHEMBL4747506	0	1
CHEMBL5187554	0	1
CHEMBL5276925	0	1

Drugs: Cyclophosphamide, Acalabrutinib, Azacitidine, Epcoritamab, Glofitamab, Polatuzumab Vedotin, Tafasitamab, Zanubrutinib, Golcadomide, Lisocabtagene Maraleucel